Separate terms with OR to return results that match either term.
 
Clear All

9,186 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Ascending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50742-0189-21 50742-0189 methylprednisolone METHYLPREDNISOLONE 4.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Jan. 17, 2019 July 20, 2020 In Use
50742-0401-02 50742-0401 Irinotecan Hydrochloride Irinotecan Hydrochloride 40.0 mg/2mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 5, 2017 In Use
50742-0402-05 50742-0402 Irinotecan Hydrochloride Irinotecan Hydrochloride 100.0 mg/5mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous June 5, 2017 In Use
50742-0404-01 50742-0404 Topotecan Topotecan 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 7, 2016 In Use
50742-0405-10 50742-0405 Oxaliplatin Oxaliplatin 50.0 mg/10mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 29, 2018 In Use
50742-0406-20 50742-0406 Oxaliplatin Oxaliplatin 100.0 mg/20mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Oct. 29, 2018 In Use
50742-0416-05 50742-0416 zoledronic acid Zoledronic acid 4.0 mg/5mL Ancillary Therapy Bisphosphonate Intravenous Feb. 19, 2020 In Use
50742-0420-01 50742-0420 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0423-10 50742-0423 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0427-05 50742-0427 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0428-02 50742-0428 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 7, 2017 April 30, 2021 In Use
50742-0430-01 50742-0430 decitabine DECITABINE 50.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Sept. 25, 2019 In Use
50742-0431-08 50742-0431 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 7, 2017 In Use
50742-0438-10 50742-0438 arsenic trioxide ARSENIC TRIOXIDE 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Nov. 15, 2018 In Use
50742-0445-05 50742-0445 Carboplatin Carboplatin 50.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Feb. 12, 2018 In Use
50742-0446-15 50742-0446 Carboplatin Carboplatin 150.0 mg/15mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Feb. 12, 2018 In Use
50742-0447-45 50742-0447 Carboplatin Carboplatin 450.0 mg/45mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Dec. 31, 2021 No Longer Used
50742-0448-60 50742-0448 Carboplatin Carboplatin 600.0 mg/60mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Feb. 28, 2022 No Longer Used
50742-0463-16 50742-0463 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 7, 2017 In Use
50742-0464-50 50742-0464 Leucovorin Calcium Leucovorin Calcium 10.0 mg/mL Ancillary Therapy Chemoprotective Antidote Intramuscular, Intravenous Nov. 23, 2018 In Use
50742-0477-01 50742-0477 MELPHALAN HYDROCHLORIDE MELPHALAN HYDROCHLORIDE Chemotherapy Alkylating Agent Nitrogen Mustard Feb. 18, 2020 In Use
50742-0481-20 50742-0481 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0482-50 50742-0482 fluorouracil FLUOROURACIL 2.5 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0483-99 50742-0483 fluorouracil FLUOROURACIL 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0485-05 50742-0485 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 29, 2020 In Use
50742-0494-17 50742-0494 levoleucovorin LEVOLEUCOVORIN 10.0 mg/mL Ancillary Therapy Intravenous May 8, 2018 July 31, 2021 In Use
50742-0495-25 50742-0495 levoleucovorin LEVOLEUCOVORIN 10.0 mg/mL Ancillary Therapy Intravenous May 8, 2018 June 30, 2021 In Use
50742-0496-26 50742-0496 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 26, 2019 In Use
50742-0497-53 50742-0497 gemcitabine GEMCITABINE 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 26, 2019 In Use
50742-0498-05 50742-0498 Gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 26, 2019 In Use
50742-0512-20 50742-0512 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sept. 27, 2018 In Use
50742-0519-02 50742-0519 cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2020 In Use
50742-0520-05 50742-0520 cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous July 30, 2020 In Use
50742-0521-10 50742-0521 Cyclophosphamide CYCLOPHOSPHAMIDE 200.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Nov. 19, 2021 In Use
50742-0525-07 50742-0525 arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Jan. 27, 2021 In Use
50881-0005-60 50881-0005 Ruxolitinib Jakafi 5.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov. 16, 2011 In Use
50881-0010-01 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov. 16, 2011 In Use
50881-0010-60 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov. 16, 2011 In Use
50881-0015-60 50881-0015 Ruxolitinib Jakafi 15.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov. 16, 2011 In Use
50881-0020-60 50881-0020 Ruxolitinib Jakafi 20.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov. 16, 2011 In Use
50881-0025-60 50881-0025 Ruxolitinib Jakafi 25.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov. 16, 2011 In Use
50881-0026-01 50881-0026 Pemigatinib PEMAZYRE 4.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
50881-0027-01 50881-0027 Pemigatinib PEMAZYRE 9.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
50881-0028-01 50881-0028 Pemigatinib PEMAZYRE 13.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
51013-0190-09 51013-0190 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Oral May 29, 2018 In Use
51013-0190-30 51013-0190 Dutasteride Dutasteride 0.5 mg/1 Ancillary Therapy Oral May 29, 2018 In Use
51079-0321-01 51079-0321 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 13, 2015 June 30, 2019 No Longer Used
51079-0321-20 51079-0321 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 13, 2015 June 30, 2019 No Longer Used
51079-0321-30 51079-0321 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 13, 2015 June 30, 2019 No Longer Used
51079-0321-56 51079-0321 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral July 17, 2015 Dec. 31, 2018 No Longer Used

Found 9,186 results in 21 millisecondsExport these results